0001192482-20-000291.txt : 20200420
0001192482-20-000291.hdr.sgml : 20200420
20200420194231
ACCESSION NUMBER: 0001192482-20-000291
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200417
FILED AS OF DATE: 20200420
DATE AS OF CHANGE: 20200420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HENWOOD GERALDINE
CENTRAL INDEX KEY: 0001236451
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36329
FILM NUMBER: 20803686
MAIL ADDRESS:
STREET 1: 88 SIDNEY ST
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Recro Pharma, Inc.
CENTRAL INDEX KEY: 0001588972
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261523233
STATE OF INCORPORATION: PA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 LAPP ROAD
CITY: MALVERN
STATE: PA
ZIP: 19355
BUSINESS PHONE: (484) 395-2400
MAIL ADDRESS:
STREET 1: 490 LAPP ROAD
CITY: MALVERN
STATE: PA
ZIP: 19355
4/A
1
edgar.xml
PRIMARY DOCUMENT
X0306
4/A
2020-04-17
2020-04-20
0001588972
Recro Pharma, Inc.
REPH
0001236451
HENWOOD GERALDINE
C/O RECRO PHARMA, INC.
490 LAPP ROAD
MALVERN
PA
19355
1
1
0
0
President and CEO
Common Stock
2020-04-17
4
M
0
80000
2.47
A
321194
D
Common Stock
2020-04-17
4
S
0
80000
8.22
D
241194
D
Common Stock
50000
I
By: Spouse
Employee Stock Option (Right to Buy)
2.47
2020-04-17
4
M
0
80000
0
D
2024-12-16
Common Stock
80000
0
D
This amended Form 4 is being filed to reflect an exercise of options that occurred on the same day as the transaction.
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.51, inclusive. The reporting person undertakes to provide Recro Pharma, Inc., any security holder of Recro Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1 to this Form 4.
The shares subject to this option are fully vested and exercisable.
/s/ Ryan D. Lake, attorney-in-fact
2020-04-20